晨光生物 (300138.SZ) Latest Company News

Sep 1, 2026, 11:53 UTC
Chenguang Biotech announced that as of August 31, 2026, it had repurchased 925,900 shares of its own stock for a total of 10.35 million yuan.
Source:
- finance.sina.cn
Aug 24, 2026, 10:07 UTC
Chenguang Biotech Group announced its 2026 first-half results, with net profit attributable to shareholders of 179 million yuan, down 16.95% year-on-year.
Aug 19, 2026, 07:13 UTC
Chenguang Biotech announced on August 19 that it has strategically entered synthetic biology and is developing related products, including a rebaudioside M biosynthesis project and a lycopene bio-fermentation project.
Source:
- finance.sina.cn
Aug 14, 2026, 07:54 UTC
Chenguang Biotech received an administrative supervision measure decision from the Xinjiang Securities Regulatory Bureau, which ordered it to rectify and issued a warning letter due to non-operational fund occupation of 136 million yuan from a subsidiary.
Source:
- finance.sina.cn
Jul 15, 2026, 10:23 UTC
Chenguang Biotech's wholly-owned subsidiary Shache Chenguang obtained a 30 million yuan credit line from China Merchants Bank, with Chenguang Biotech providing joint liability guarantee.
Source:
- finance.sina.cn
Jul 15, 2026, 10:23 UTC
Chenguang Biotech's subsidiary Bazhou Shengyuan repaid a 2 billion yuan loan, reducing the company's corresponding guarantee obligation.
Source:
- finance.sina.cn
Jul 2, 2026, 10:26 UTC
Chenguang Biotech's controlling shareholder Lu Qingguo proposes to repurchase company shares using 80 million to 160 million yuan of self-owned funds via centralized bidding on the Shenzhen Stock Exchange.
Source:
- finance.sina.cn

300138.SZ

Chenguang Biotech announced that as of August 31, 2026, it had repurchased 925,900 shares of its own stock for a total of 10.35 million yuan.

Chenguang Biotech Group announced its 2026 first-half results, with net profit attributable to shareholders of 179 million yuan, down 16.95% year-on-year.

Chenguang Biotech announced on August 19 that it has strategically entered synthetic biology and is developing related products, including a rebaudioside M biosynthesis project and a lycopene bio-fermentation project.

Chenguang Biotech received an administrative supervision measure decision from the Xinjiang Securities Regulatory Bureau, which ordered it to rectify and issued a warning letter due to non-operational fund occupation of 136 million yuan from a subsidiary.

Chenguang Biotech's wholly-owned subsidiary Shache Chenguang obtained a 30 million yuan credit line from China Merchants Bank, with Chenguang Biotech providing joint liability guarantee.

Chenguang Biotech's subsidiary Bazhou Shengyuan repaid a 2 billion yuan loan, reducing the company's corresponding guarantee obligation.

Chenguang Biotech's controlling shareholder Lu Qingguo proposes to repurchase company shares using 80 million to 160 million yuan of self-owned funds via centralized bidding on the Shenzhen Stock Exchange.